Intra-Cellular Therapies Inc. (ITCI) and Midatech Pharma Plc (NASDAQ:MTP) Contrasting side by side

We will be contrasting the differences between Intra-Cellular Therapies Inc. (NASDAQ:ITCI) and Midatech Pharma Plc (NASDAQ:MTP) as far as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intra-Cellular Therapies Inc. 9 0.00 47.34M -2.82 0.00
Midatech Pharma Plc 1 0.00 8.60M -0.85 0.00

Table 1 highlights Intra-Cellular Therapies Inc. and Midatech Pharma Plc’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Intra-Cellular Therapies Inc. 522,516,556.29% -45.8% -41.3%
Midatech Pharma Plc 898,172,323.76% 0% 0%

Analyst Ratings

The next table highlights the given recommendations and ratings for Intra-Cellular Therapies Inc. and Midatech Pharma Plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Intra-Cellular Therapies Inc. 0 0 2 3.00
Midatech Pharma Plc 0 0 0 0.00

Intra-Cellular Therapies Inc. has a 88.97% upside potential and an average target price of $18.5.

Institutional and Insider Ownership

Institutional investors held 79.5% of Intra-Cellular Therapies Inc. shares and 0% of Midatech Pharma Plc shares. Intra-Cellular Therapies Inc.’s share held by insiders are 0.8%. On the other hand, insiders held about 32.1% of Midatech Pharma Plc’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Intra-Cellular Therapies Inc. 2.2% -40.48% -37.5% -28.51% -57.38% -26.69%
Midatech Pharma Plc -5.52% 9.23% -23.76% 28.33% -74.97% -0.65%

For the past year Intra-Cellular Therapies Inc. was more bearish than Midatech Pharma Plc.

Summary

On 6 of the 10 factors Midatech Pharma Plc beats Intra-Cellular Therapies Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. The company also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy. In addition, it is involved in the research and development of various product candidates in the areas of oncology and neuroscience, including ophthalmology; and immunotherapy. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.